Home / GU oncology / UTUC / Adjuvant after nephroureterectomy

Upper tract urothelial carcinoma → Adjuvant treatment after nephroureterectomy

Last reviewed: 2026-09-22 · Next review: 2026-12-21

current — POUT supports adjuvant gemcitabine–platinum for its eligible postoperative population

Who this applies to

Population	Exact POUT boundary	Noneligible boundary
Resected high-risk UTUC	Predominantly transitional-cell UTUC after en-bloc radical nephroureterectomy; pT2–pT4, any N, M0 or pT any, N1–3, M0¹.	Metastatic disease, residual lymphadenopathy when postoperative imaging was required, or disease outside these pathologic criteria¹.
Fit for postoperative platinum	Treatment began within 90 days; satisfactory hematologic/biochemical profile; GFR ≥30 mL/min¹.	Do not generalize the protocol to frail patients with preserved GFR but another cisplatin contraindication¹⁴.
Protocol platinum selection	GFR ≥50: gemcitabine–cisplatin; GFR 30–49: gemcitabine–carboplatin¹.	POUT was not designed to compare cisplatin with carboplatin¹.

Standard options

Clinical context	Option	Key inclusion	Typical course
pT2–T4 and/or pN+ UTUC after RNU, no prior neoadjuvant platinum	Adjuvant gemcitabine–platinum¹	POUT eligibility and organ function¹.	Four 21-day cycles beginning within 90 days after RNU¹.
No prior bladder cancer after RNU	Single postoperative intravesical chemotherapy³⁴	Bladder-recurrence prevention, not systemic recurrence treatment³⁴.	Separate perioperative intervention per guideline³⁴.
Platinum-ineligible or declining platinum, high-risk UC	Discuss adjuvant nivolumab only with explicit evidence boundary⁴⁶	Regulatory all-MIUC option; UTUC subgroup benefit was not established in the retrieved guideline⁴⁶.	Individualized⁴⁶.

Therapy sequencing

Postoperative state	Next treatment order	Branch point / evidence boundary
pT2–T4 and/or pN+ UTUC after RNU, no prior neoadjuvant platinum	Start four cycles of adjuvant gemcitabine–platinum within the POUT postoperative window¹.	This is the direct POUT sequence; it does not compare adjuvant chemotherapy with neoadjuvant chemotherapy¹.
Post-RNU GFR ≥50 mL/min	Gemcitabine–cisplatin¹.	This is POUT protocol selection, not a universal cisplatin eligibility definition¹.
Post-RNU GFR 30–49 mL/min	Gemcitabine–carboplatin¹.	POUT was not designed to compare cisplatin with carboplatin¹.
Platinum-ineligible or declining, high-risk disease	Discuss nivolumab or trial/surveillance with explicit UTUC evidence limits⁴⁶.	CheckMate 274 is all-MIUC; do not claim an unreported UTUC subgroup efficacy result⁴⁶.
No prior bladder cancer after RNU	Deliver the separate single intravesical postoperative chemotherapy intervention³⁴.	This reduces bladder recurrence; it is not systemic recurrence treatment³⁴.

Surveillance and treatment de-escalation

Post-RNU imaging and cystoscopy schedule

Modality	Through 24 months	Years 3–5	Notes
CT chest/abdomen/pelvis⁴	Every 6 months × 2 years⁴	Annually⁴	EAU UTUC surveillance framework⁴.
Cystoscopy (bladder-recurrence surveillance)¹⁴	Every 6 months × 2 years¹	Annually through 60 months¹	POUT methods schedule for lower-tract recurrence; EAU likewise emphasizes bladder surveillance after RNU¹⁴.

Phase	Monitoring cadence	Stop, hold, or de-escalate	Re-escalation / next line
After RNU (surveillance arm or post-chemo)	CT and cystoscopy per schedule above; single postoperative intravesical chemotherapy when indicated¹³⁴.	Complete four cycles of adjuvant gemcitabine–platinum within 90 days if selected; then surveillance only¹⁴.	Local recurrence → re-resection when feasible; metastatic recurrence → systemic therapy (metastatic UTUC/mUC page)⁴⁶.
On adjuvant gemcitabine–platinum	CBC, renal function, electrolytes each cycle; audiometry if cisplatin¹⁴.	Stop after four cycles per POUT; hold for febrile neutropenia or renal decline¹.	Progression on therapy → systemic second-line options; platinum-ineligible may discuss nivolumab with explicit all-MIUC evidence boundary⁴⁶.

Bladder recurrence surveillance is distinct from systemic UTUC recurrence monitoring³⁴.

Published DFS landmarks only: 3-year 71% vs 46% (primary); 5-year 62% vs 45% (final); not a full KM reconstruction¹².

Landmark evidence

Trial	Population	Intervention	Comparator	Primary endpoint	Clinically meaningful outcomes	Generalizability-critical differences
POUT primary analysis, N=261	Post-RNU pT2–T4 and/or pN+ M0 UTUC, fit for platinum¹	Gemcitabine plus cisplatin or protocol-defined carboplatin ×4¹	Surveillance¹	Disease-free survival¹	Three-year DFS 71% vs 46%; HR 0.45 (0.30–0.68)¹.	Open-label; platinum choice was renal-function defined, not randomized¹.
POUT final report	Same population²	Gemcitabine–platinum ×4²	Surveillance²	Disease-free survival²	Five-year DFS 62% vs 45%; HR 0.55 (0.38–0.80)². Five-year OS 66% vs 57%; univariable HR 0.68, while adjusted OS HR 0.76 (0.51–1.12)².	The OS result is an updated univariable signal, not a definitive adjusted OS benefit².
CheckMate 274	All high-risk MIUC after radical resection⁴⁶	Nivolumab for 1 year⁴⁶	Placebo⁴⁶	Disease-free survival⁴⁶	Grade ≥3 treatment-related AEs 17.9% vs 7.2%⁴⁶.	All-MIUC trial; do not report an unverified UTUC subgroup efficacy estimate⁴⁶.

Biomarkers

Marker	Current clinic role	Emerging / investigational	How it changes decision now	Limits
pT / pN	POUT treatment selection for adjuvant gemcitabine–platinum¹	—	Confirms who is inside the pivotal postoperative population¹.	Confirm postoperative imaging when required for nodal disease¹.
Renal function / GFR	Protocol platinum choice (cisplatin if GFR ≥50; carboplatin if 30–49)¹	—	Selects gemcitabine–cisplatin vs gemcitabine–carboplatin within POUT rules¹.	POUT GFR thresholds are trial-specific, not a universal cisplatin eligibility definition¹.
PD-L1	Not a substitute for UTUC-specific adjuvant IO evidence⁴⁶	Exploratory in all-MIUC adjuvant ICI trials⁴⁶	Does not establish a UTUC-only nivolumab/pembrolizumab standard⁴⁶.	Do not assign an unreported UTUC subgroup effect⁴⁶.
FGFR / HER2	Not adjuvant selectors after RNU⁴⁶	Metastatic biomarker-directed therapy if recurrence⁴⁶	No change to adjuvant platinum vs surveillance choice on this page¹⁴.	Metastatic-context assays only; not used to select adjuvant chemotherapy¹⁴.
ctDNA	Not standard for adjuvant selection after RNU⁴	Investigational MRD correlatives in urothelial disease⁴	Do not withhold or add adjuvant therapy based on ctDNA outside a protocol⁴.	No practice-ready adjuvant assay on this page⁴.

Upcoming research

Field direction: UTUC-specific adjuvant systemic research remains thin; all-MIUC adjuvant IO trials (for example AMBASSADOR) inform counseling but do not create a UTUC-only standard⁴⁶.

No care-changing prospective UTUC-specific result was identified in the retrieved source pack⁴⁶. AMBASSADOR is peer-reviewed all-MIUC evidence and does not establish a UTUC-specific standard⁴⁶.

Toxicity

Regimen and comparator	Trial-level safety outcomes	Selected named toxicities	Counseling focus
Gemcitabine–platinum versus surveillance, POUT	Acute grade ≥3 treatment-emergent events: 44% vs 4% with surveillance; no treatment-related deaths¹.	Chemotherapy-arm named events (treatment-arm rates; surveillance-arm named-event % not retained here): grade ≥3 neutrophil decrease 36%, platelet decrease 10%, nausea 6%, febrile neutropenia 6%, vomiting 6%¹.	Contact oncology urgently for fever, infection symptoms, bleeding, uncontrolled vomiting, or dehydration; monitor blood counts and renal function¹.
Nivolumab versus placebo, CheckMate 274 all MIUC	Grade ≥3 treatment-related events 17.9% vs 7.2%⁴⁶.	Pruritus 23.1%, fatigue 17.4%, diarrhea 16.8%; grade ≥3 lipase elevation 5.1%; all are all-MIUC, not UTUC-specific⁴⁶.	Promptly report diarrhea, abdominal pain, cough/dyspnea, rash, fatigue, jaundice, or endocrine symptoms; immune effects can require hold, steroids, or hormone replacement⁴⁶.

On-treatment monitoring

SOC/option regimen	Hallmark monitoring toxicity and published rate	Patient action / clinic response
Gemcitabine–cisplatin or gemcitabine–carboplatin	POUT chemotherapy-arm named events (treatment-arm rates): grade ≥3 neutrophil decrease 36%, platelet decrease 10%, nausea 6%, febrile neutropenia 6%, and vomiting 6%; trial-level grade ≥3 events 44% vs 4% with surveillance¹.	Check CBC, renal function, electrolytes, neuropathy/hearing, and nausea/vomiting; fever, infection symptoms, bleeding, reduced urine output, new hearing change, or uncontrolled vomiting needs urgent assessment¹.
Single postoperative intravesical chemotherapy	A comparable named adverse-event rate was not retrieved in this systemic-adjuvant source set³⁴.	Review dysuria, hematuria, fever, and urinary symptoms after instillation; fever or escalating urinary symptoms requires prompt contact³⁴.
Nivolumab when platinum is unsuitable	CheckMate 274 all-MIUC: grade ≥3 treatment-related events 17.9% vs 7.2%; pruritus 23.1%, fatigue 17.4%, diarrhea 16.8%⁴⁶.	Review bowel, lung, liver, skin, and endocrine symptoms before each dose; persistent diarrhea/abdominal pain, cough/dyspnea, jaundice, or marked fatigue needs prompt contact⁴⁶.

Epic phrase

#utucadjuvant

Counseling: POUT adjuvant gemcitabine–platinum after RNU: 3-year disease-free survival about 71 in 100 vs 46 in 100 with surveillance (HR 0.45 vs surveillance); 5-year DFS about 62% vs 45% with surveillance (HR 0.55 vs surveillance). Five-year OS 66% vs 57% with surveillance; adjusted OS HR 0.76 vs surveillance (CI crossed 1)—DFS is the established benefit. Nivolumab adjuvant data are from all-MIUC CheckMate 274 versus placebo, not a verified UTUC subgroup estimate.
Counseling: Reviewed surveillance and de-escalation: four adjuvant gemcitabine–platinum cycles then stop; CT chest/abdomen/pelvis and cystoscopy every 6 months ×2 years then annually (POUT methods for cystoscopy; EAU CT framework); single postoperative intravesical chemotherapy when indicated; metastatic recurrence → systemic pathway.
Counseling: Reviewed sequence: post-RNU → four cycles of gemcitabine–platinum; use cisplatin at POUT GFR ≥50 and carboplatin at GFR 30–49. Single intravesical chemotherapy is a separate bladder-recurrence intervention; nivolumab for platinum-ineligible disease requires an explicit all-MIUC evidence discussion. ***
Monitoring: With gemcitabine–platinum, check CBC, renal function, electrolytes, neuropathy/hearing, and nausea/vomiting. With nivolumab, review bowel, lung, liver, skin, and endocrine symptoms; after intravesical treatment, review fever, worsening urinary symptoms, dysuria, and hematuria. Contact oncology urgently for fever, infection symptoms, bleeding, uncontrolled vomiting, dehydration, or concerning immune symptoms. ***
Decision: *** selects adjuvant gemcitabine–platinum / surveillance / further recovery or trial assessment.
Labs/NGS: CBC, CMP, renal function *, pathology stage *, postoperative imaging ***.
Procedures: *** intravesical recurrence-prevention discussion and multidisciplinary review.
Follow-up: *** treatment monitoring, cystoscopic/bladder surveillance, and imaging.

Edit markdown

Guideline references

Sources

Changelog

2026-09-22: Added explicit POUT/EAU cystoscopy every 6 months ×2 years then annually alongside CT; inserted POUT DFS landmark figure; expanded Biomarkers to five-column table; mirrored cystoscopy + CT cadence in paired dotphrase.
2026-09-22: Renamed Upcoming trial results to Upcoming research; reframed for ongoing trials and field direction.
2026-09-22: Named surveillance comparator in POUT toxicity/monitoring counseling rates; mirrored comparator-named efficacy counseling in the paired dotphrase.
2026-09-22: Added line-level source superscripts ([^n]) linked to numbered Sources.
2026-09-22: Added Surveillance and treatment de-escalation section; strengthened quantified benefit counseling in dotphrase.

2026-09-21: Added post-RNU therapy sequencing and all-option on-treatment monitoring, retaining the all-MIUC boundary for nivolumab.
2026-09-21: Created post-nephroureterectomy UTUC page with POUT eligibility, outcomes, and trial-first toxicity counseling.

Edit evidence markdown

Evidence page